Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

EQUIPAPHARM : revenue, balance sheet and financial ratios

EQUIPAPHARM is a French company founded 9 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in NIMES (30000), this company of category PME shows in 2025 a net income positive of 34 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EQUIPAPHARM (SIREN 828753517)
Indicator 2025
Revenue N/C
Net income 34 303 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2025, EQUIPAPHARM generates positive net income of 34 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

34 303 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 197%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 20%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

196.814%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

19.711%

Solvency indicators evolution
EQUIPAPHARM

Sector positioning

Debt ratio
196.81 2025
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Watch

In 2025, the debt ratio of EQUIPAPHARM (196.81) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
19.71% 2025
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Watch

In 2025, the financial autonomy of EQUIPAPHARM (19.7%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Positioning of EQUIPAPHARM in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of EQUIPAPHARM is estimated at 28 180 € (range 10 725€ - 102 911€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
10k€ 28k€ 102k€
28 180 € Range: 10 725€ - 102 911€
NAF 5 all-time

Valuation method used

Net Income Multiple
34 303 € × 0.8x = 28 180 €
Range: 10 726€ - 102 911€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare EQUIPAPHARM with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about EQUIPAPHARM

What is the revenue of EQUIPAPHARM ?

The revenue of EQUIPAPHARM is not publicly disclosed (confidential accounts filed with INPI).

Is EQUIPAPHARM profitable?

Yes, EQUIPAPHARM generated a net profit of 34 k€ in 2025.

Where is the headquarters of EQUIPAPHARM ?

The headquarters of EQUIPAPHARM is located in NIMES (30000), in the department Gard.

Where to find the tax return of EQUIPAPHARM ?

The tax return of EQUIPAPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EQUIPAPHARM operate?

EQUIPAPHARM operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.